BerGenBio ASA Valuation
| BRRGF Stock | USD 0.97 0.00 0.00% |
Today, the firm appears to be overvalued. BerGenBio ASA shows a prevailing Real Value of $0.93 per share. The current price of the firm is $0.97. Our model approximates the value of BerGenBio ASA from analyzing the firm fundamentals such as Return On Equity of -0.96, operating margin of (383.14) %, and Shares Outstanding of 88.66 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that BerGenBio ASA's price fluctuation is abnormally volatile at this time. Calculation of the real value of BerGenBio ASA is based on 3 months time horizon. Increasing BerGenBio ASA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BerGenBio pink sheet is determined by what a typical buyer is willing to pay for full or partial control of BerGenBio ASA. Since BerGenBio ASA is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BerGenBio Pink Sheet. However, BerGenBio ASA's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.97 | Real 0.93 | Hype 0.97 | Naive 0.71 |
The real value of BerGenBio Pink Sheet, also known as its intrinsic value, is the underlying worth of BerGenBio ASA Company, which is reflected in its stock price. It is based on BerGenBio ASA's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BerGenBio ASA's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of BerGenBio ASA helps investors to forecast how BerGenBio pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BerGenBio ASA more accurately as focusing exclusively on BerGenBio ASA's fundamentals will not take into account other important factors: BerGenBio ASA Total Value Analysis
BerGenBio ASA is currently forecasted to have takeover price of 36.1 M with market capitalization of 207.74 M, debt of 1.02 M, and cash on hands of 509.41 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the BerGenBio ASA fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
36.1 M | 207.74 M | 1.02 M | 509.41 M |
BerGenBio ASA Investor Information
About 35.0% of the company shares are held by company insiders. The book value of BerGenBio ASA was currently reported as 1.86. The company recorded a loss per share of 0.35. BerGenBio ASA had not issued any dividends in recent years. Based on the key measurements obtained from BerGenBio ASA's financial statements, BerGenBio ASA is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.BerGenBio ASA Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BerGenBio ASA has an asset utilization ratio of 0.17 percent. This implies that the Company is making $0.001719 for each dollar of assets. An increasing asset utilization means that BerGenBio ASA is more efficient with each dollar of assets it utilizes for everyday operations.BerGenBio ASA Ownership Allocation
BerGenBio ASA holds a total of 88.66 Million outstanding shares. BerGenBio ASA retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.BerGenBio ASA Profitability Analysis
The company reported the revenue of 774 K. Net Loss for the year was (309.36 M) with profit before overhead, payroll, taxes, and interest of 774 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates BerGenBio ASA's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in BerGenBio ASA and how it compares across the competition.
About BerGenBio ASA Valuation
The pink sheet valuation mechanism determines BerGenBio ASA's current worth on a weekly basis. Our valuation model uses a comparative analysis of BerGenBio ASA. We calculate exposure to BerGenBio ASA's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BerGenBio ASA's related companies.BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. The company was incorporated in 2007 and is headquartered in Bergen, Norway. Bergenbio is traded on OTC Exchange in the United States.
8 Steps to conduct BerGenBio ASA's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates BerGenBio ASA's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct BerGenBio ASA's valuation analysis, follow these 8 steps:- Gather financial information: Obtain BerGenBio ASA's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine BerGenBio ASA's revenue streams: Identify BerGenBio ASA's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research BerGenBio ASA's industry and market trends, including the size of the market, growth rate, and competition.
- Establish BerGenBio ASA's growth potential: Evaluate BerGenBio ASA's management, business model, and growth potential.
- Determine BerGenBio ASA's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate BerGenBio ASA's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for BerGenBio Pink Sheet analysis
When running BerGenBio ASA's price analysis, check to measure BerGenBio ASA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BerGenBio ASA is operating at the current time. Most of BerGenBio ASA's value examination focuses on studying past and present price action to predict the probability of BerGenBio ASA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BerGenBio ASA's price. Additionally, you may evaluate how the addition of BerGenBio ASA to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |